Tumour cells disseminated to lymph nodes, peripheral blood and bone marrow: a crucial problem in breast cancer.

Significance, detection and markers of disseminated breast cancer
cells.
by Marc Lacroix
InTextoResearch, Baelen, Wallonia, Belgium & Jules Bordet Institute,
Brussels, Belgium
Now in Endocrine-Related Cancer 13 (4) 1033-1067 (December 2006)

http://erc.endocrinology-journals.or...full/13/4/1033


The development of distant metastases is the major cause of death from
breast cancer. In order to predict and prevent tumour spreading, many
attempts are being made to detect small numbers of tumour cells that
have shed from the primary lesions and have moved to lymph nodes, blood

or bone marrow. A review presents the advantages and limitations of
techniques used for disseminated tumour cells (DTC) detection in breast

cancer. DTC markers are listed and the most currently used of them
(KRT19/CYTOKERATIN 19, CEACAM5/CEA, TACSTD1/GA733-2/TROP1/M4S1/EPCAM,
MUC1/CA15.3/CA27.29, EGFR, ERBB2/HER2/NEU, SCGB2A2/MGB1/MAMMAGLOBIN,
SCGB2A1/MGB2/MAMMAGLOBIN2, SCGB1D2/LIPOPHILIN B/BU101, PIP/GCDFP15,
SBEM/BS106/B511S, TFF1/pS2, TFF3, ANKRD30A/NY-BR-1/B726P, SPDEF/PDEF,
ESR1/ESTROGEN RECEPTOR, SERPINB5/MASPIN, and GABRP) are discussed,
notably on the basis of recent data on breast tumour portraits
("luminal epithelial-like", "basal/myoepithelial-like" and
"ERBB2/Her2/neu"). The significance of DTC for prognosis and
prediction of response to therapy is examined. DTC viability, the
notion of cell dormancy and the concept of breast cancer stem cells are

also discussed.

scimedweb@mail.com wrote:

> Significance, detection and markers of disseminated breast cancer
> cells.
> by Marc Lacroix

You missed 998 other active newsgroups.
J